IFN‐α triggers the transition from M2 to M1 to neutralize the proliferative and migratory effects on HCC, simultaneously expanding CD8+T‐cell infiltration in HCC and enhancing the therapeutic effect of sorafenib.41 Here, CD8A is linked to hepatocellular carcinoma.